Floatz logo

Docosahexaenoic Acid

Ductal Breast Carcinoma In Situ

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Ductal Breast Carcinoma In Situ cohort.

Asset / SponsorPhaseRating
ROPIVACAINE
Zealand University Hospital
Phase 4BB
SUFENTANYL
Zealand University Hospital
Phase 4BB
TAMOXIFEN
Northwestern University
Phase 3BB
(Z)-Endoxifen
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Phase 2BB
Metformin
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Docosahexaenoic Acid is also rated in:

obesity disorderDormant
BBB
Indicative ·
72 / 100
View asset →
ProdromeDormant
BB
Indicative ·
68 / 100
View asset →
Non-alcoholic Fatty Liver Disease (NAFLD)Dormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →